CY1119854T1 - Ανθρωπινο μονοκλωνικο αντισωμα με ειδικοτητα για ε πρωτεϊνη ιου δαγκειου πυρετου οροτυπου 1 και χρησεις αυτου - Google Patents

Ανθρωπινο μονοκλωνικο αντισωμα με ειδικοτητα για ε πρωτεϊνη ιου δαγκειου πυρετου οροτυπου 1 και χρησεις αυτου

Info

Publication number
CY1119854T1
CY1119854T1 CY20171101173T CY171101173T CY1119854T1 CY 1119854 T1 CY1119854 T1 CY 1119854T1 CY 20171101173 T CY20171101173 T CY 20171101173T CY 171101173 T CY171101173 T CY 171101173T CY 1119854 T1 CY1119854 T1 CY 1119854T1
Authority
CY
Cyprus
Prior art keywords
protein
human
monoclonic
specialty
dengue virus
Prior art date
Application number
CY20171101173T
Other languages
English (en)
Inventor
Paul Anthony Macary
Ee Ping Evelyn Teoh
Brendon John Hanson
En Wei Teo
Angeline Pei Chiew Lim
Mah Lee Mary Ng
Shee Mei Lok
Petra Eveliina Kukkaro
Original Assignee
National University Of Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National University Of Singapore filed Critical National University Of Singapore
Publication of CY1119854T1 publication Critical patent/CY1119854T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Παρέχονται συνθέσεις και μέθοδοι για την θεραπευτική αγωγή ή πρόληψη μόλυνσης από ιό δάγκειου πυρετού σε ένα σπονδυλωτό υποκείμενο. Συγκεκριμένα, αποκαλύπτονται ανθρώπινα εξουδετεροποιητικά μονοκλωνικά αντισώματα κατά του ιού δάγκειου πυρετού που έχουν απομονωθεί από Β κύτταρα αθανατοποιημένα με ΕΜΒ προερχόμενα από ασθενείς που έχουν αναρρώσει από μόλυνση ιού δάγκειου πυρετού. Παρέχονται μέθοδοι για χορήγηση τέτοιων αντισωμάτων σε ένα σπονδυλωτό υποκείμενο σε μία ποσότητα αποτελεσματική για να μειώσει, εξαλείψει ή να προλάβει υποτροπή της μόλυνσης.
CY20171101173T 2010-12-14 2017-11-08 Ανθρωπινο μονοκλωνικο αντισωμα με ειδικοτητα για ε πρωτεϊνη ιου δαγκειου πυρετου οροτυπου 1 και χρησεις αυτου CY1119854T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42308510P 2010-12-14 2010-12-14
PCT/SG2011/000436 WO2012082073A1 (en) 2010-12-14 2011-12-14 Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof

Publications (1)

Publication Number Publication Date
CY1119854T1 true CY1119854T1 (el) 2018-06-27

Family

ID=46244986

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171101173T CY1119854T1 (el) 2010-12-14 2017-11-08 Ανθρωπινο μονοκλωνικο αντισωμα με ειδικοτητα για ε πρωτεϊνη ιου δαγκειου πυρετου οροτυπου 1 και χρησεις αυτου

Country Status (27)

Country Link
US (2) US9376486B2 (el)
EP (1) EP2651975B1 (el)
JP (2) JP6483337B2 (el)
KR (2) KR101904232B1 (el)
CN (1) CN103534270B (el)
AU (2) AU2011341744B2 (el)
BR (1) BR112013015129B1 (el)
CA (1) CA2821268C (el)
CO (1) CO6801636A2 (el)
CY (1) CY1119854T1 (el)
DK (1) DK2651975T3 (el)
EA (1) EA201390874A1 (el)
ES (1) ES2644236T3 (el)
HR (1) HRP20171580T1 (el)
HU (1) HUE035609T2 (el)
IL (1) IL226957B (el)
LT (1) LT2651975T (el)
MX (1) MX348152B (el)
MY (1) MY166537A (el)
PH (1) PH12017501075A1 (el)
PL (1) PL2651975T3 (el)
PT (1) PT2651975T (el)
RS (1) RS56737B1 (el)
SG (2) SG10201510111PA (el)
SI (1) SI2651975T1 (el)
WO (1) WO2012082073A1 (el)
ZA (1) ZA201304459B (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010003450A (es) 2007-09-26 2010-04-27 Chugai Pharmaceutical Co Ltd Region constante de anticuerpo modificada.
MY166537A (en) 2010-12-14 2018-07-10 Nat Univ Singapore Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
EP2834265A4 (en) * 2012-04-02 2015-10-14 Univ North Carolina METHODS AND COMPOSITIONS FOR DENGUE VIRUS EPITOPES
WO2014064707A1 (en) * 2012-10-26 2014-05-01 International Centre For Genetic Engineering And Biotechnology Pichia pastoris -expressed dengue virus like particles
ES2745431T3 (es) * 2013-06-26 2020-03-02 Univ North Carolina Chapel Hill Composiciones para vacunas contra el virus del dengue y su uso
CA2938590C (en) 2014-02-11 2023-10-17 Visterra, Inc. Antibody molecules to dengue virus and uses thereof
CN114773470A (zh) 2015-02-05 2022-07-22 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
CN109311986A (zh) 2016-03-25 2019-02-05 威特拉公司 登革热病毒抗体分子的制剂
CA3026050A1 (en) 2016-08-05 2018-02-08 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of il-8 related diseases
SG10201607778XA (en) * 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
CN112119090B (zh) 2018-03-15 2023-01-13 中外制药株式会社 对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
US10526398B2 (en) * 2018-06-12 2020-01-07 National Defense Medical Center Anti-dengue virus antibodies and applications thereof
WO2020033491A1 (en) * 2018-08-07 2020-02-13 Chan Zuckerberg Biohub, Inc. Antibodies against dengue virus and related methods
US20230018080A1 (en) * 2019-11-20 2023-01-19 The University Of North Carolina At Chapel Hill Methods and compositions for recombinant dengue viruses or vaccine and diagnostic development
WO2022162009A1 (en) 2021-01-26 2022-08-04 Eth Zurich Method for rapid identification of cross-reactive and/or rare antibodies
WO2022161597A1 (en) * 2021-01-26 2022-08-04 Eth Zurich Method for rapid identification of cross-reactive and/or rare antibodies

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
DE3223885A1 (de) 1982-06-26 1983-12-29 Basf Ag, 6700 Ludwigshafen Makroporoese, hydrophile traeger fuer enzyme
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5651991A (en) 1987-10-28 1997-07-29 Nippon Shinyaku Co. Ltd. Drug carriers
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
KR940003548U (ko) 1992-08-14 1994-02-21 김형술 세탁물 건조기
CA2134348C (en) 1993-02-26 2007-01-02 Hideo Nogusa Polysaccharide derivatives and drug carriers
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
IL128774A (en) 1994-03-07 2001-05-20 Dow Chemical Co A preparation containing a dendritic polymer in a complex with at least one unit of biological reaction sub
WO1995025764A1 (fr) 1994-03-23 1995-09-28 Meiji Seika Kabushiki Kaisha Derive bicatenaire de lipide contenant un polyoxyethylene
JP3699141B2 (ja) 1994-09-24 2005-09-28 伸彦 由井 超分子構造の生体内分解性医薬高分子集合体及びその調製方法
US5490840A (en) 1994-09-26 1996-02-13 General Electric Company Targeted thermal release of drug-polymer conjugates
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6106866A (en) 1995-07-31 2000-08-22 Access Pharmaceuticals, Inc. In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
EA006972B1 (ru) 1998-12-23 2006-06-30 Пфайзер Инк. Моноклональное антитело человека к ctla-4 и способы его применения
WO2001014424A2 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
US20040126829A1 (en) 2001-12-18 2004-07-01 Hildebrand William H. Anti-HLA assay and methods
WO2003080672A1 (en) 2002-03-22 2003-10-02 Aprogen, Inc. Humanized antibody and process for preparing same
WO2005056600A2 (en) 2003-12-08 2005-06-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind or neutralize dengue virus
TWI445547B (zh) * 2007-06-08 2014-07-21 Nat Health Research Institutes 登革熱病毒胜肽疫苗及其製備與使用方法
GB0724065D0 (en) 2007-12-10 2008-01-16 Sparrow Paul A A spirit level
EP2294192A4 (en) 2008-06-09 2011-11-23 Jolla Inst Allergy Immunolog COMPOSITIONS AND METHODS OF TREATMENT AND VACCINATION AGAINST DENGUE VIRUS (DV)
AU2009305113B2 (en) 2008-10-13 2015-07-16 Institute For Research In Biomedicine Dengue virus neutralizing antibodies and uses thereof
WO2010093335A1 (en) * 2009-02-10 2010-08-19 Nanyang Technological University Antibodies for diagnosis and treatment of flaviviral infections
MY166537A (en) * 2010-12-14 2018-07-10 Nat Univ Singapore Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof

Also Published As

Publication number Publication date
RS56737B1 (sr) 2018-03-30
DK2651975T3 (en) 2017-10-30
AU2011341744B2 (en) 2016-09-08
US9376486B2 (en) 2016-06-28
CA2821268C (en) 2021-06-15
PH12017501075B1 (en) 2018-02-12
US10294293B2 (en) 2019-05-21
CN103534270A (zh) 2014-01-22
ES2644236T3 (es) 2017-11-28
CN103534270B (zh) 2017-03-08
PH12017501075A1 (en) 2018-02-12
JP6483337B2 (ja) 2019-03-13
JP2014502839A (ja) 2014-02-06
BR112013015129A2 (pt) 2018-10-09
LT2651975T (lt) 2018-02-12
BR112013015129B1 (pt) 2022-11-16
EP2651975B1 (en) 2017-08-09
KR101781546B1 (ko) 2017-09-26
CO6801636A2 (es) 2013-11-29
IL226957B (en) 2020-03-31
US20170029489A1 (en) 2017-02-02
EA201390874A1 (ru) 2013-12-30
MX348152B (es) 2017-06-02
AU2011341744A1 (en) 2013-07-18
PT2651975T (pt) 2017-11-14
ZA201304459B (en) 2019-11-27
AU2016269515A1 (en) 2017-01-05
EP2651975A1 (en) 2013-10-23
KR20140019777A (ko) 2014-02-17
EP2651975A4 (en) 2014-05-21
HRP20171580T1 (hr) 2018-01-26
WO2012082073A1 (en) 2012-06-21
KR101904232B1 (ko) 2018-10-05
PL2651975T3 (pl) 2018-04-30
HUE035609T2 (hu) 2018-05-28
CA2821268A1 (en) 2012-06-21
SG10201510111PA (en) 2016-01-28
JP2018046835A (ja) 2018-03-29
MY166537A (en) 2018-07-10
SG191155A1 (en) 2013-07-31
US20130259871A1 (en) 2013-10-03
MX2013006710A (es) 2014-09-25
SI2651975T1 (en) 2018-03-30
KR20170110159A (ko) 2017-10-10

Similar Documents

Publication Publication Date Title
CY1119854T1 (el) Ανθρωπινο μονοκλωνικο αντισωμα με ειδικοτητα για ε πρωτεϊνη ιου δαγκειου πυρετου οροτυπου 1 και χρησεις αυτου
CY1119751T1 (el) Υλικα και μεθοδοι για θεραπεια ή προληψη ασθενειων που σχετιζονται me her-3
CY1120297T1 (el) Ρυθμιστες υποδοχεα ανδρογονου και χρησεις αυτων
CY1122816T1 (el) Στοχοθετημενοι συνδετικοι παραγοντες εναντι β7-η1
CY1120417T1 (el) Μεθοδοι για τη μειωση των επιπεδων των βασεοφιλων
CY1124144T1 (el) Συνθεσεις και μεθοδοι για θεραπεια εγκεφαλικου επεισοδιου σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
CY1122676T1 (el) Αντισωματα εναντι της κλαυδινης 18.2 που ειναι χρησιμα στη διαγνωση του καρκινου
CY1119445T1 (el) Αντισωματα εναντι του ανθρωπινου gdf8
CY1120471T1 (el) Αντισωματα κατα του cd70
CY1120412T1 (el) Μορια εξανθρωπισμενου αντισωματος ειδικα για il-31
CR20130016A (es) ANTICUERPOS PEPTIDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
CY1113640T1 (el) Μεθοδοι για την θεραπευτικη αγωγη ρευματοειδους αρθριτιδας
CY1114123T1 (el) Ανθρωπινα αντισωματα υψηλης συγγενειας εναντιον ανθρωπινου υποδοχεα il-4
CY1114271T1 (el) Αντισωματα εξουδετερωσης, ανθρωπινου κυτταρομεγαλοϊου και χρηση αυτων
CY1117942T1 (el) Αντισωματα προσδεματος επαγωγης πολλαπλασιασμου (april)
BR112012022214A2 (pt) métodos e composições para tratar doença de degos
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
CY1123240T1 (el) Αντισωμα αντι fgf23 και μια φαρμακευτικη συνθεση που το περιλαμβανει
CY1120772T1 (el) ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ
MY166776A (en) Humanised anti-ctla4 antibodies
BR112012018951B8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
CY1121167T1 (el) Βελτιωμενα αντισωματα εναντι της ανθρωπινης φρακταλκινης και χρησεις αυτων
BR112013002831A2 (pt) anticorpos direcionados contra a il-17
CY1118918T1 (el) Παραγοντες εξαλειψης κυτταρων β, οπως αντισωματα enanti-cd20 ή θραυσματα αυτων για την αντιμετωπιση συνδρομου χρονιας κοπωσης
CY1118967T1 (el) Φαρμακευτικες συνθεσεις υψηλης δοσης βιοτινης